Overview

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
Phase:
Phase 4
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Collaborator:
Sanofi
Treatments:
Antibodies, Monoclonal